CN1838959A - Erbb2抗癌剂的给药方案 - Google Patents

Erbb2抗癌剂的给药方案 Download PDF

Info

Publication number
CN1838959A
CN1838959A CNA200480023705XA CN200480023705A CN1838959A CN 1838959 A CN1838959 A CN 1838959A CN A200480023705X A CNA200480023705X A CN A200480023705XA CN 200480023705 A CN200480023705 A CN 200480023705A CN 1838959 A CN1838959 A CN 1838959A
Authority
CN
China
Prior art keywords
methyl
inhibitor
yloxy
pyridin
quinazolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200480023705XA
Other languages
English (en)
Chinese (zh)
Inventor
萨米特·K·巴塔查亚
理查德·D·康奈尔
詹姆斯·D·莫耶
吉蒂什·P·贾尼
丹尼斯·A·诺埃
斯蒂法纳斯·J·斯泰恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1838959A publication Critical patent/CN1838959A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA200480023705XA 2003-08-18 2004-08-06 Erbb2抗癌剂的给药方案 Pending CN1838959A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49591903P 2003-08-18 2003-08-18
US60/495,919 2003-08-18

Publications (1)

Publication Number Publication Date
CN1838959A true CN1838959A (zh) 2006-09-27

Family

ID=34193358

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200480023705XA Pending CN1838959A (zh) 2003-08-18 2004-08-06 Erbb2抗癌剂的给药方案

Country Status (18)

Country Link
US (1) US20050119288A1 (cg-RX-API-DMAC10.html)
EP (1) EP1658080A1 (cg-RX-API-DMAC10.html)
JP (1) JP2007502807A (cg-RX-API-DMAC10.html)
KR (2) KR20060037447A (cg-RX-API-DMAC10.html)
CN (1) CN1838959A (cg-RX-API-DMAC10.html)
AR (1) AR045268A1 (cg-RX-API-DMAC10.html)
AU (1) AU2004264726A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0413745A (cg-RX-API-DMAC10.html)
CA (1) CA2536140A1 (cg-RX-API-DMAC10.html)
CO (1) CO5670356A2 (cg-RX-API-DMAC10.html)
IL (1) IL173127A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA06001989A (cg-RX-API-DMAC10.html)
NO (1) NO20061252L (cg-RX-API-DMAC10.html)
RU (1) RU2328287C2 (cg-RX-API-DMAC10.html)
SG (1) SG135193A1 (cg-RX-API-DMAC10.html)
TW (1) TW200522966A (cg-RX-API-DMAC10.html)
WO (1) WO2005016347A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200600517B (cg-RX-API-DMAC10.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
US8505468B2 (en) * 2002-11-19 2013-08-13 Sharp Kabushiki Kaisha Substrate accommodating tray
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
JP4828421B2 (ja) * 2003-08-14 2011-11-30 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
BRPI0414532B1 (pt) 2003-09-19 2018-06-05 Astrazeneca Ab Composto derivado de quinazolina, processo para preparar 0 mesmo, composição farmaceutica, e, uso de um composto derivado de quinazolina
HRP20110958T1 (hr) 2004-05-06 2012-01-31 Warner-Lambert Company Llc 4-fenilaminokinazolin-6-ilamidi
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
US20080194596A1 (en) * 2005-06-03 2008-08-14 Frizer Inc. Therapeutic Combination Including a Selective Erbb2 Inhibitor
CN102772358A (zh) * 2005-06-16 2012-11-14 美瑞德生物工程公司 药物组合物及其用途
WO2007014335A2 (en) * 2005-07-27 2007-02-01 The University Of Texas System Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
AU2006315512B2 (en) * 2005-11-14 2012-11-01 Ariad Pharmaceuticals, Inc. Administration of an mTOR inhibitor to treat patients with cancer
DE602006021645D1 (de) 2005-11-15 2011-06-09 Array Biopharma Inc Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
EP2010911A4 (en) * 2006-03-31 2009-05-13 Massachusetts Inst Technology TREATMENT OF EGF RECEPTOR MUTANTS EXPRESSING TUMORS
CN101415411A (zh) * 2006-04-05 2009-04-22 诺瓦提斯公司 用于治疗癌症的治疗剂组合
CA2669415A1 (en) 2006-11-14 2008-05-22 Ariad Pharmaceuticals, Inc. Solid dosage form comprising ap23573
KR20100016385A (ko) * 2007-04-10 2010-02-12 미리어드 파마슈티칼스, 인코포레이티드 뇌종양 치료방법
NZ580867A (en) * 2007-04-10 2011-02-25 Myriad Pharmaceuticals Inc Method of treating melanoma
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
CA2720989A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Methods for treating cancer
EP2144887A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER
WO2008154249A2 (en) * 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2009137714A2 (en) * 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
WO2010027848A2 (en) * 2008-08-26 2010-03-11 Teva Pharmaceutical Industries Ltd. Forms of lapatinib compounds and processes for the preparation thereof
KR20150036824A (ko) 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
CN105940096B (zh) 2014-01-31 2019-11-05 凸版印刷株式会社 生物分子分析试剂盒及生物分子分析方法
CN108473538B (zh) * 2015-10-28 2022-01-28 塔弗达治疗有限公司 Sstr靶向缀合物及其颗粒和制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA932522B (en) * 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
ATE446955T1 (de) * 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CN1437594A (zh) * 2000-06-22 2003-08-20 辉瑞产品公司 用于治疗异常细胞生长的取代的双环衍生物
CN1608062A (zh) * 2001-12-12 2005-04-20 辉瑞产品公司 E－2－甲氧基－n－(3－{4－[3－甲基－4－(6－甲基－吡啶－3－基氧基) －苯氨基]－喹唑啉－6基}－烯丙基)－乙酰胺的盐，其制备和抗癌用途
IL161908A0 (en) * 2001-12-12 2005-11-20 Pfizer Prod Inc Quinazoline derivatives for the treatment of abnormal cell growth
NZ540092A (en) * 2002-11-20 2007-06-29 Array Biopharma Inc Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
KR20050085749A (ko) * 2002-12-18 2005-08-29 화이자 프로덕츠 인크. 비정상적 세포 성장의 치료를 위한 4-아닐리노 퀴나졸린유도체

Also Published As

Publication number Publication date
AR045268A1 (es) 2005-10-19
US20050119288A1 (en) 2005-06-02
RU2006102125A (ru) 2007-09-27
BRPI0413745A (pt) 2006-10-24
CO5670356A2 (es) 2006-08-31
RU2328287C2 (ru) 2008-07-10
JP2007502807A (ja) 2007-02-15
KR20060037447A (ko) 2006-05-03
AU2004264726A1 (en) 2005-02-24
WO2005016347A1 (en) 2005-02-24
IL173127A0 (en) 2006-06-11
KR20080014144A (ko) 2008-02-13
ZA200600517B (en) 2007-02-28
CA2536140A1 (en) 2005-02-24
TW200522966A (en) 2005-07-16
EP1658080A1 (en) 2006-05-24
MXPA06001989A (es) 2006-05-17
SG135193A1 (en) 2007-09-28
NO20061252L (no) 2006-05-16

Similar Documents

Publication Publication Date Title
CN1177833C (zh) 取代的间二氮杂萘衍生物
RU2328287C2 (ru) Схема приема erbb2 противоопухолевых агентов
TWI758623B (zh) Ｂｃｌ-２抑制劑與ＢＴＫ抑制劑的組合產品在預防和/或治療疾病中的用途
CN100351241C (zh) 喹唑啉胺盐酸盐的稳定多晶形物及其制备方法和医药用途
CN1100540C (zh) 具有选择性抑制her－2自磷酸化性质的蛋白质酪氨酸激酶芳基和杂芳基喹唑啉化合物
US8426428B2 (en) EGFR kinase knockdown via electrophilically enhanced inhibitors
JP5740409B2 (ja) キナーゼ阻害剤
CN117357650A (zh) 包含sos1抑制剂的药物组合物
CN101035536A (zh) 有机化合物的组合
JP2017214387A (ja) 増殖性疾患の治療のためのｈｓｐ９０阻害剤と組み合わせた２−カルボキサミドシクロアミノウレア誘導体
CN1909908A (zh) 用于治疗蛋白激酶依赖性疾病的吡唑并[1,5－a]嘧啶－7－基－胺衍生物
CN1856327A (zh) Vegf受体抑制剂与化疗剂的组合
TW201728583A (zh) 氨基噻唑化合物及其用途
CN1791396A (zh) 组蛋白脱乙酰基酶抑制剂与化疗剂的组合
MXPA06005024A (es) Combinaciones de inhibidor de erbb2 selectivo/anticuerpos anti-erbb en el tratamiento del cancer.
JP2014040446A (ja) Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して耐性を獲得した疾患を治療するためのピリミジン誘導体の使用
TWI667236B (zh) 作為蛋白激酶抑制劑的胺基噻唑化合物
JP2008542354A (ja) 癌治療におけるｅｒｂＢ２阻害剤と他の治療薬の併用
EP3174869B1 (en) Combination therapy of a met inhibitor and an egfr inhibitor
TWI774780B (zh) 化合物
CN101222850A (zh) 治疗对药物有抗性的癌症的方法
BRPI0717873A2 (pt) Derivado de 3-amino-pirazol-4-carboxamida úteis como inibidores de proteína quinases
HK1091745A (en) Dosing schedule for erbb2 anticancer agents
WO2016025641A1 (en) Combinations of an erk inhibitor and an egfr inhibitor and related methods
EP4034121A1 (en) Treatment of egfr mutant-related cancers using a combination of egfr and cdk4/6 inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1091745

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20060927

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1091745

Country of ref document: HK